Low Raymond Anthony 4
4 · SCICLONE PHARMACEUTICALS INC · Filed Oct 16, 2017
Insider Transaction Report
Form 4
Low Raymond Anthony
VP, Finance & Controller
Transactions
- Exercise/Conversion
Common Stock
2017-10-13+11,250→ 37,748 total - Exercise/Conversion
Restricted Stock Unit
2017-10-13−2,500→ 0 total→ Common Stock (2,500 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2017-10-13$1.53/sh−10,574$16,178→ 0 totalExercise: $9.65Exp: 2027-03-08→ Common Stock (10,574 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$1.53/sh−24,426$37,372→ 0 totalExercise: $9.65Exp: 2027-03-08→ Common Stock (24,426 underlying) - Disposition to Issuer
Common Stock
2017-10-13$11.18/sh−37,748$422,023→ 0 total - Disposition to Issuer
Incentive Stock Option (right to buy)
2017-10-13$2.06/sh−15,923$32,801→ 0 totalExercise: $9.12Exp: 2026-03-15→ Common Stock (15,923 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$6.43/sh−50,000$321,500→ 0 totalExercise: $4.75Exp: 2023-10-15→ Common Stock (50,000 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$2.06/sh−19,077$39,299→ 0 totalExercise: $9.12Exp: 2026-03-15→ Common Stock (19,077 underlying) - Exercise/Conversion
Restricted Stock Unit
2017-10-13−5,000→ 0 total→ Common Stock (5,000 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2017-10-13$2.35/sh−31,012$72,878→ 0 totalExercise: $8.83Exp: 2025-03-16→ Common Stock (31,012 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$2.35/sh−3,988$9,372→ 0 totalExercise: $8.83Exp: 2025-03-16→ Common Stock (3,988 underlying) - Exercise/Conversion
Restricted Stock Unit
2017-10-13−3,750→ 0 total→ Common Stock (3,750 underlying)
Footnotes (10)
- [F1]Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement.
- [F10]Under its terms the option became exercisable in installments with 25% vesting on March 8, 2018 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
- [F2]Includes 216 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on October 6, 2017 and 746 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on August 31, 2017.
- [F3]Granted under Issuer's 2005 Equity Incentive Plan.
- [F4]Under its terms the option became exercisable in installments with 25% vesting on October 15, 2014 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger").
- [F5]The option was canceled immediately prior to the Merger in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
- [F6]Under its terms the option became exercisable in installments with 25% vesting on March 16, 2016 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
- [F7]Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock.
- [F8]Granted under Issuer's 2015 Equity Incentive Plan.
- [F9]Under its terms the option became exercisable in installments with 25% vesting on March 15, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.